Literature DB >> 27202272

Cost-Effectiveness Evaluation of Brentuximab Vedotin for Refractory/Relapsed Hodgkin Lymphoma: A Comparative Analysis of the Results of Mexico and Venezuela.

B Meza-Torres1, J G Gay1, D E Jakouloff2.   

Abstract

Year:  2014        PMID： 27202272     DOI： 10.1016/j.jval.2014.08.2290

Source DB:  PubMed          Journal:  Value Health        ISSN： 1098-3015            Impact factor:   5.725


× No keyword cloud information.
  1 in total

1.  Economic evaluation of brentuximab vedotin for persistent Hodgkin lymphoma.

Authors:  V Babashov; M A Begen; J Mangel; G S Zaric
Journal:  Curr Oncol       Date:  2017-02-27       Impact factor: 3.677
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.